AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00305539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg sc / for 3 months
Study NCT00305539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04897880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
Study NCT03248427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
Study NCT03248427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Daily continuous
Study NCT03248427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60 mg/m2 as a continuous IV perfusion
Study NCT03248427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 600 MG/M2 in a 30 minutes IV infusion
Study NCT03248427 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m2, in one hour IV infusion
Study NCT04435028 — intervention group
Intervention type: DRUG
Intervention: Ketotifen 1 MG
Description: Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
Study NCT02180048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg of caffeine/day (Two 200mg pills/day)
Description: One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
Study NCT02180048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg of caffeine/day (One 200mg pill and one placebo pill)
Description: This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
Study NCT02272374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF creation
Study NCT02272374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCC placement
Study NCT02272374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVG creation
Study NCT03408613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: See arm/group description
Study NCT02180048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Two placebo pills/day
Description: This arm will have participants consume two placebo pills each day.
Study NCT03408613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: See arm/group description
Study NCT03408613 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: See arm/group description
Study NCT02531529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomedine
Description: intraoperative infusion
Study NCT02531529 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fentanyl
Study NCT02068313 — intervention group
Intervention type: RADIATION
Intervention: Toxicity and outcome measures of IMRT
Study NCT04040556 — intervention group
Intervention type: OTHER
Intervention: Simulation class
Description: Pediatric anesthesia simulation class for anesthesia residences
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)
Description: Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)
Description: Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa.
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT06138912 — intervention group
Intervention type: RADIATION
Intervention: plain radiography (x-ray)
Description: Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
Study NCT03853915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18-F]- FDG - PET
Description: \[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
Study NCT01654692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and Fotemustine
Description: Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e8 IU given at t=0 via IM route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e7 IU given at T=0 via the IM route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e7 IU given at t=0 via the SC route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e8 IU given at T=0 via the SC route
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT00652951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study NCT01508780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)
Description: All subjects will have OCT and IVUS imaging during their right heart catheterization.
Study NCT01508780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Intravascular Ultrasound
Description: All subjects will have OCT and IVUS imaging during their right heart catheterization.
Study NCT02107599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Description: No Florbetapir (18F) will be administered in this study.
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
Study NCT02656641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Client Feedback
Description: Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
Study NCT02656641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Self Feedback
Description: Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
Study NCT00006489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Study NCT00006489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Daily dosing 100 mg for 24 weeks
Study NCT00006489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill Placebo daily dosing 24 weeks
Study NCT03255343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMDENDRIM
Description: In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
Study NCT02201537 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: renal echography
Description: Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS
Study NCT03433664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
Study NCT03183414 — intervention group
Intervention type: OTHER
Intervention: echocardiographic measurements
Description: echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
Study NCT05888129 — intervention group
Intervention type: PROCEDURE
Intervention: surgery after neoadjuvant chemotherapy
Description: surgery after neoadjuvant chemotherapy
Study NCT00647127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine: 20microg/h
Study NCT00647127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl: 25microg/h
Study NCT00647127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Study NCT03169946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT with CHX-MTZ,OFD
Description: Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
Study NCT06030375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KAND567
Description: Continuous intravenous infusion for 6 hours
Study NCT06030375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion for 6 hours
Study NCT00181714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate HCl (Concerta)
Description: OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
Study NCT01890408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wound infusion ropivacaine
Description: Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours.
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo given at T=0 via the IM route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo given at T=0 via the SC route
Study NCT01835223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (1mg)
Description: Given PO
Study NCT01835223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5mg)
Description: Given PO
Study NCT00303485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 6 months
Study NCT03169946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT with CHX,OFD
Description: Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
Study NCT03047109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
Study NCT03047109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: 30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
Study NCT03448315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: motor cortex stimulation (2 mA, 20 min for 4 sessions)
Study NCT03448315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: motor cortex stimulation (2 mA, 20 min for 4 sessions)
Study NCT04846725 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context.
Study NCT03575884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Time Reduction Curriculum
Description: Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year.
Study NCT00117559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Treatment
Description: Participants receive a 15-minute telephone call for 8 weeks
Study NCT00113659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
Study NCT00113659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
Study NCT00253383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT00253383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Study NCT00253383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00253383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00253383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT00253383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00253383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT02614911 — intervention group
Intervention type: OTHER
Intervention: Biological sampling
Description: Biological sampling including blood, feces, biopsies...
Study NCT03666078 — intervention group
Intervention type: PROCEDURE
Intervention: cesarean delivery
Description: women delivered by cesarean section
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Infidelity Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sexual Infidelity Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Infidelity Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotional Infidelity Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Player in Jealousy Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Player in Jealousy Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Player in Non-Jealousy Condition
Study NCT03067805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Player in Non-Jealousy Condition
Study NCT02040610 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Proton Therapy
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and 8 weeks via the IM route
Study NCT00440362 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and 8 weeks via the SC route
Study NCT03055208 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gamma knife radiosurgery (15 Gy to 50% isodose)
Description: Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: Six-Minute Walk Test
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: 10-Meter Walk Test
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: 30-Second Chair Stand
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: Linear Analog Scale of Function
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: Modified Brief Fatigue Inventory
Study NCT01952821 — intervention group
Intervention type: OTHER
Intervention: FACIT-Fatigue
Study NCT01572012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron solution 4 mg single administration
Study NCT01572012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Hylenex
Description: Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
Study NCT01572012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT
Description: Zofran ODT (8 mg) single administration
Study NCT01572012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron solution
Description: Ondansetron solution (4 mg) single administration
Study NCT03494764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
Study NCT01370499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT01370499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
Study NCT03641599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiographic assessment of the RV and LV systolic function
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 0.1mg/kg.
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 0.3mg/kg
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 1.0 mg/kg.
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 3.0 mg/kg.
Study NCT00771420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAM-3001
Description: Dosed at 10 mg/kg.
Study NCT00771420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active: Placebo 5:1 for arms 2-6
Study NCT04487275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC901 or Placebo
Description: groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months